Search Results - "Abenhardt, W"

Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group by Hoechstetter, M A, Busch, R, Eichhorst, B, Bühler, A, Winkler, D, Eckart, M J, Vehling-Kaiser, U, Schimke, H, Jäger, U, Hurtz, H J, Hopfinger, G, Hartmann, F, Fuss, H, Abenhardt, W, Blau, I, Freier, W, Müller, L, Goebeler, M, Wendtner, C M, Bahlo, J, Fischer, K, Bentz, M, Emmerich, B, Döhner, H, Hallek, M, Stilgenbauer, S

Get full text

PO-0798: Bevacizumab treatment in recurrent malignant glioma patients – mono-institutional experience in 125 patients by Niyazi, M, Thorsteinsdottir, J, Fleischmann, D.F, Abenhardt, W, Tonn, J.C, Belka, C, Schnell, O

Get full text

Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer by Stemmler, H J, diGioia, D, Freier, W, Tessen, H W, Gitsch, G, Jonat, W, Brugger, W, Kettner, E, Abenhardt, W, Tesch, H, Hurtz, H J, Rösel, S, Brudler, O, Heinemann, V

“…Background: An increasing proportion of patients are exposed to anthracyclines and/or taxanes in the adjuvant or neoadjuvant setting. Re-exposure in the…”
Get full text

Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial by Stintzing, S, Fischer von Weikersthal, L, Vehling-Kaiser, U, Stauch, M, Hass, H G, Dietzfelbinger, H, Oruzio, D, Klein, S, Zellmann, K, Decker, T, Schulze, M, Abenhardt, W, Puchtler, G, Kappauf, H, Mittermüller, J, Haberl, C, Giessen, C, Moosmann, N, Heinemann, V

“…Background: The AIO KRK-0104 randomised phase II trial investigated the efficacy and safety of two capecitabine-based regimens: combination of capecitabine and…”
Get full text

PCN13 Treatment of Patients with Multiple Myeloma (TLN-Registry): A “Real Life” Overview of Treatment by Office-Based Oncologists in Germany by Hartmann, H, Knauf, W, Abenhardt, W, Aldaoud, A, Lerchenmüller, C, Koska, M

Get full text

High efficacy and low toxicity of weekly docetaxel given as first-line treatment for metastatic breast cancer by Stemmler, J, Mair, W, Stauch, M, Papke, J, Deutsch, G, Abenhardt, W, Dorn, B, Kentenich, C, Malekmohammadi, M, Jackisch, C, Leinung, S, Brudler, O, Vehling-Kaiser, U, Stamp, J, Heinemann, V

“…Docetaxel is one of the most effective antitumor agents currently available for the treatment of metastatic breast cancer (MBC). This phase II multicenter…”
Get more information

9146 Long term benefit from erlotinib treatment is independent of prognostic factors and therapeutic response by Schumann, C, Heigener, D, Dittrich, I, Abenhardt, W, Dederke, B, Duell, T, Matzdorff, A, Raack, B.W, Steins, M, Schneider, C.P

Get full text

Treatment of chemotherapy-induced nausea and vomiting with 5-hydroxytryptamine type 3 receptor antagonists by Abenhardt, W, Bosse, D, Böning, L, Bojko, P, Hitz, H, Völkl, S, Fromm, M, Mittermüller, J, Göldel, N, Schick, H-D, Dietzfelbinger, H, Hinke, A

“…5-hydroxytryptamine 3 (5-HT3) receptor antagonists have proved to be highly efficacious in the prevention and treatment of chemotherapy-induced nausea and…”
Get more information

Abstract P6-17-37: Therapy landscape of patients with metastatic, HER2 positive breast cancer - Data from the real world breast cancer registry PRAEGNANT (NCT02338167) by Lux, MP, Hartkopf, AD, Huober, J, Volz, B, Taran, F-A, Overkamp, F, Hadji, P, Tesch, H, Haeberle, L, Ettl, J, Lueftner, DI, Wallwiener, M, Müller, V, Beckmann, MW, Belleville, E, Wimberger, P, Hielscher, C, Geberth, M, Lermann, J, Abenhardt, W, Kurbacher, C, Wuerstlein, R, Thomssen, C, Untch, M, Fasching, PA, Janni, W, Fehm, TN, Wallwiener, D, Brucker, SY, Schneeweiss, A, Kolberg, H-C

“…Abstract Purpose: This analysis describes comprehensive real-world data concerning the use of anti-HER2 therapies in HER2 positive metastatic breast cancer…”
Get full text

Abstract P6-17-22: Progression free survival (PFS) and overall survival (OS) of patients treated with trastuzumab emtansine (T-DM1) after previous treatment with pertuzumab in patients with advanced breast cancer (NCT02338167) by Schneeweiss, A, Lux, MP, Hartkopf, AD, Volz, B, Kolberg, H-C, Hadji, P, Tesch, H, Haeberle, L, Ettl, J, Lüftner, DI, Wallwiener, M, Müller, V, Beckmann, MW, Belleville, E, Wimberger, P, Hielscher, C, Geberth, M, Lermann, J, Abenhardt, W, Kurbacher, C, Wuerstlein, R, Thomssen, C, Untch, M, Overkamp, F, Huober, J, Taran, F-A, Janni, W, Wallwiener, D, Brucker, SY, Fasching, PA, Fehm, TN

“…Abstract Background Studies leading to the approval of trastuzumab emtansine (T-DM1) have been conducted without pertuzumab as previous therapy. Therefore data…”
Get full text

PS1163 PATIENT‐BASED PROSPECTIVE REAL WORLD DATA ANALYSIS SHOWS THAT THE DURATION OF TREATMENT INTERRUPTIONS WITH SUBSEQUENT RESUMPTION OF IDELALISIB THERAPY CAN VARY FROM DAYS TO MONTHS by Hoechstetter, M., Knauf, W., Eissmann, P., Hucke, N., Ramroth, H., Abenhardt, W., Rummel, M.

“…Background: Idelalisib, a first‐in‐class PI3Kδ‐inhibitor, is licensed in the European Union in relapsed chronic lymphocytic leukemia (CLL) and refractory…”
Get full text

Abstract P5-21-09: Overall survival of metastatic breast cancer patients – data from the PRAEGNANT breast cancer registry by Taran, F-A, Fasching, PA, Volz, B, Huober, J, Overkamp, F, Kolberg, HC, Hadji, P, Tesch, H, Haeberle, L, Ettl, J, Lux, MP, Hartkopf, AD, Lueftner, D, Wallwiener, M, Müller, V, Beckmann, MW, Belleville, E, Wimberger, P, Hielscher, C, Geberth, M, Fersis, N, Abenhardt, W, Kurbacher, C, Wuerstlein, R, Thomssen, C, Untch, M, Janni, W, Fehm, TN, Wallwiener, D, Brucker, SY, Schneeweiss, A

“…Abstract Background Breast Cancer registries can help to understand how patient groups are treated outside clinical trials and what outcome is to expected for…”
Get full text

Abstract P3-11-07: Factors associated with first line chemotherapy use in patients with hormone receptor positive, HER2 negative metastatic breast cancer – data from the PRAEGNANT breast cancer registry by Huober, J, Fasching, PA, Taran, F-A, Volz, B, Overkamp, F, Kolberg, HC, Hadji, P, Tesch, H, Haeberle, L, Ettl, J, Hartkopf, AD, Lux, MP, Lueftner, D, Wallwiener, M, Mueller, V, Beckmann, MW, Belleville, E, Wimberger, P, Hielscher, C, Geberth, M, Fersis, N, Abenhardt, W, Kurbacher, C, Wuerstlein, R, Thomssen, C, Untch, M, Janni, W, Wallwiener, D, Brucker, SY, Schneeweiss, A, Fehm, TN

“…Abstract Background For breast cancer patients with metastases which are not life threatening national and international guidelines recommend the exhaustion of…”
Get full text

FDG-PET: an important tool in the diagnosis of lung cancer by Abenhardt, Wolfgang

Get more information

Abstract P3-14-19: Long-Time Tumor Remissions under Trastuzumab Therapy in HER2- Positive Locally Recurrent or Metastatic Breast Cancer: First Interim Analysis of the HER-OS Database by Jaenicke, F, Mueller, V, Abenhardt, W, Kaufmann, M, Schoenegg, W, Schneeweiss, A.

“…Abstract Introduction Currently, locally recurrent or metastatic breast cancer is incurable and considered a chronic disease. Although pallitative endocrine…”
Get full text

Idarubicin monotherapy in multiply pretreated leukemia patients : response in relation to P-glycoprotein expression by NÜSSLER, V, GIESELER, F, KOLB, H.-J, WILMANNS, W, ZWIERZINA, H, GULLIS, E, PELKA-FLEISCHER, R, DIEM, H, ABENHARDT, W, SCHMITT, R, LANGENMAYER, I, WOHLRAB, A

“…The aim of the study was to test whether fractionated (weekly) idarubicin administration to multiply pretreated leukemia patients is effective and tolerable…”
Get full text

Treatment of Non-transplant patients with multiple myeloma: routine treatment by office-based haematologists in Germany--data from the prospective Tumour Registry Lymphatic Neoplasms (TLN) by Knauf, Wolfgang, Abenhardt, Wolfgang, Aldaoud, Ali, Nusch, Arnd, Grugel, Renate, Münz, Michaela, Hartmann, Holger, Marschner, Norbert

“…Various treatment options exist for patients with multiple myeloma (MM). Clinical registries provide insight into routine treatment and identify changes in…”
Get more information

Ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative advanced breast cancer (ABC) who received no prior therapy for advanced disease by Grischke, EM, Nusch, A, Marschner, N, Abenhardt, W, Wilke, J, Decker, T, Just, M, Kümmel, S, Kurbacher, C, Marmé, F, Overkamp, F, Xuan, F, Miller, M, Janni, W

“…Introduction: Ribociclib, a selective, small-molecule inhibitor of CDK4/6, has exhibited antitumor activity as part of doublet or triplet therapy…”
Get full text

Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer (mCRC): AIO KRK-0104 trial by Heinemann, V., Fischer von Weikersthal, L., Vehling-Kaiser, U., Stauch, M., Hass, H., Dietzfelbinger, H. F., Oruzio, D. V., Klein, S., Zellmann, K., Decker, T., Schulze, M., Abenhardt, W., Puchtler, G., Kappauf, H. W., Mittermueller, J., Haberl, C., Giessen, C. A., Moosmann, N., Stintzing, S.

“…Abstract only…”
Get full text

Weekly versus 3-weekly docetaxel (D2) plus doxorubicin (D4) for first-line treatment of metastatic breast cancer (MBC) by Stemmler, H., Harbeck, N., Groell der Rivera, I., Vehling-Kaiser, U., Rauthe, G., Abenhardt, W., Sommer, H., Meerpohl, H., Kiechle, M., Heinemann, V.

“…Abstract only 1101 Background: We investigated the toxicity and efficacy of weekly applied docetaxel compared to its standard 3-weekly application in pts…”
Get full text